Omics of HER2-positive breast cancer

OMICS A Journal of Integrative Biology

Volumn 17, Issue 3, 2013, Pages 119-129

  Bravatà, Valentina ^a,b   Cammarata, Francesco Paolo ^a,b   Forte, Giusi Irma ^a,b   Minafra, Luigi ^a,b  

^a CNR   (Italy)

^b Laboratorio di Tecnologie Oncologiche (LATO) HSR GGiglio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; LAPATINIB; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB;

ADD ON THERAPY; APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER RESEARCH; CANCER RESISTANCE; CELL CYCLE ARREST; CELL PROLIFERATION; COPY NUMBER VARIATION; DNA METHYLATION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENOME ANALYSIS; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TRANSCRIPTOMICS; TUMOR GENE;

ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; GENES, ERBB-2; GENOMICS; HUMANS; PROTEOMICS; RECEPTOR, ERBB-2; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875137889     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2012.0099     Document Type: Review

References (84)

1. Bai T, and Luoh SW. (2008). GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis 29, 473-479.
2. Barginear MF, John V, and Budman DR. (2012). Trastuzumab-DM1: A clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med doi:10.2119/molmed.2012.00302.
3. Baylin SB, and Ohm JE. (2006). Epigenetic gene silencing in cancer mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6,107-116.
4. Bediaga NG, Acha-Sagredo A, Guerra I, et al. (2010). DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res 12, R77.
5. Bentwich I, Avniel A, Karov Y, et al. (2005). Identification of hundreds of conserved and nonconserved human micro-RNAs. Nat Genet 37, 766-770.
6. Bloom GC, Eschrich S, Zhou JX, Coppola D, and Yeatman T. (2007). Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer 120, 769-775.
7. Boone JJ, Bhosle J, Tilby MJ, Hartley JA, and Hochhauser D. (2009). Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol. Cancer Ther 9, 3015-3023.
8. Boyd ZS, Wu QJ, O'Brien C, et al. (2008). Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther 7, 3695-3706.
9. Brouillard F, Fritsch J, Edelman A, and Ollero M. (2008). Contribution of proteomics to the study of the role of cytokeratins in disease and physiopathology. Proteomics Clin Appl 2, 264-285.
10. Castilla MÁ, Díaz-Martín J, Sarrió D, et al. (2012). MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One 7: e47709.
11. Chang GC, Liu KJ, Hsieh CL, et al. (2006). Identification of alpha-enolase as an autoantigen in lung cancer: Its overexpression is associated with clinical outcomes. Clin Cancer Res 12, 5746-5754.
12. Chen Y, and Olopade OI. (2008). MYC in breast tumor progression. Expert Rev Anticancer Ther 8, 1689-1698.
13. Cheng Q, Chang JT, Geradts J, et al. (2012). Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res 14, R62.
14. Chin K, DeVries S, Fridlyand J, et al. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541.
15. Corver WE, Middeldorp A, ter Haar NT, et al. (2008). Genomewide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations. Cancer Res 68, 10333-10340.
16. Dehqanzada ZA, Storrer CE, Hueman MT, et al. (2007). Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep 17, 687-694.
17. Dvorkin-Gheva A, and Hassell JA. (2011). Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samples. PLoS One 6, e26023.
18. Eichhorn PJ, Gili M, Scaltriti M, et al. (2008). Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68, 9221-9230.
19. Esquela-Kerscher A, and Slack FJ. (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6, 259-269.
20. Esteller M. (2007). Cancer epigenomics: DNA methylomes and histone modification maps. Nat Rev Genet 8, 286-298.
21. Esteva FJ, Guo H, Zhang S, et al. (2010). PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177, 1647-1656.
22. Faltus T, Yuan J, Zimmer B, et al. (2004). Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu- overexpressing breast cancer cells. Neoplasia 6, 786-795.
23. Fiegl H, Millinger S, Goebel G, et al. (2006). Breast cancer DNA methylation profiles in cancer cells and tumor stroma: Association with HER-2/neu status in primary breast cancer. Cancer Res 66, 29-33.
24. Fountzilas G, Valavanis C, Kotoula V, et al. (2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med 10, 10.
25. Galiè M, Sorrentino C, Montani M, et al. (2005). Mammary carcinoma provides highly tumorigenic and invasive reactive stromal cells. Carcinogenesis 26, 1868-1878.
26. Gaudet F, Hodgson JG, Eden A, et al. (2003). Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492.
27. Goddard KA, Aiello Bowles EJ, Spencer Feigelson H, et al. (2012). Utilization of HER2 genetic testing in a multiinstitutional observational study. Am J Manag Care 18, 704-712.
28. Goncalves A, and Bertucci F. (2011). Clinical application of proteomics in breast cancer: State of the art and perspectives. Med Princ Pract 20, 4-18.
29. Gown AM. (2008). Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21, S8-15.
30. Gruver AM. (2011). Molecular pathology of breast cancer: The journey from traditional practice toward embracing the complexity of a molecular classification. Arch Pathol Lab Med 135, 546-557.
31. Hamrita B, Chahed K, Kabbage M, et al. (2008). Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). Clin Chim Acta 393, 95-102.
32. Holm K, Hegardt C, Staaf J, et al. (2010). Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 12, R36.
33. Hu X, Stern HM, Ge L, et al. (2009). Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 7, 511-522.
34. Hu Z, Fan C, Oh DS, et al. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genom 7, 96.
35. Jerusalem G, Fasolo A, Dieras V, et al. (2011). Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pretreated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 125, 447-455.
36. Jones PA, and Baylin SB. (2007). The epigenomics of cancer. Cell 128, 683-692.
37. Kennecke H, Yerushalmi R, Woods R, et al. (2010). Metastatic behavior of breast cancer subtypes. J Clin Oncol 28, 3271-3277.
38. Korkaya H, Paulson A, Iovino F, and Wicha MS. (2008). HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27, 6120-6130.
39. Kouzarides T. (2007). Chromatin modifications and their function. Cell 128, 693-705.
40. Kumandan S, Mahadevan NR, Chiu K, Delaney A, and Zanetti M. (2012). Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway. Cancer Lett 11, 014.
41. Leary RJ, Lin JC, Cummins J, et al. (2008). Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 105, 16224-16229.
42. Liu JC, Voisin V, Bader GD, et al. (2012). Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER21:ERa2 breast cancer. Proc Natl Acad Sci USA 109, 5832-5837.
43. Lowery AJ, Miller N, Re M, and Kerin MJ. (2008). MicroRNAs as prognostic indicators and therapeutic targets: Potential effect on breast cancer management. Clin Cancer Res 14, 360-365.
44. Lu J, and Clark AG (2012). Impact of microRNA regulation on variation in human gene expression. Genome Res. 22, 1243-1254.
45. Ma L, Yang HY, Han XH, et al. (2012). Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer. Chin Med J 125, 4104-4110.
46. Marchiò C, Natrajan R, Shiu KK, et al. (2008). The genomic profile of HER2-amplified breast cancers: The influence of ER status. J Pathol 216, 399-407.
47. Markou A, Strati A, Malamos N, Georgoulias V, and Lianidou ES. (2011). Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 57, 421-430.
48. Mattie MD, Benz CC, Bowers J, et al. (2006). Optimized highthroughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 19, 5-24.
49. Mazouni C, Baggerly K, Hawke D, et al. (2010). Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LCMALDI-TOF/MS procedure. Proteomics 10, 3525-3532.
50. Minafra L, Norata R, Bravatà V, et al. (2012). Unmasking epithelial-mesenchymal transition in a breast cancer primary culture: A study report. BMC Res. Notes 5, 343.
51. Modi S, Stopeck A, Linden H, et al. (2011). HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on tastuzumab. Clin Cancer Res 17, 5132-5139.
52. Mojtahedi Z, Safaei A, Yousefi Z, and Ghaderi A. (2011). Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS 15, 409-418.
53. Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, et al. (2010). Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol 37, 669-678.
54. Pauletti G, Godolphin W, Press MF, and Slamon DJ (1996). Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13, 63-72.
55. Perez EA, Jenkins RB, Dueck AC, et al. (2011). C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 29, 651-659.
56. Perou CM, Sørlie T, Eisen MB, et al. (2000). Molecular portraits of human breast tumors. Nature 406, 747-752.
57. Rakha EA, El-Sayed ME, Green AR, and Lee AH. (2007). Prognostic markers in triple-negative breast cancer. Cancer 109, 25-32.
58. Reis-Filho JS, and Pusztai L. (2011). Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 378, 1812-1823.
59. Rodriguez J, Frigola J, Vendrell E, et al. (2006). Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 66, 8462-8468.
60. Schulz DM, Böllner C, Thomas G, et al. (2009). Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. Proteome Res 8, 3430-3438.
61. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, and Benz CC. (2007). Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 282, 1479-1486.
62. Shi Q, Harris LN, Lu X, et al. (2006). A declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res 5, 2947-2955.
63. Sircoulomb F, Bekhouche I, Finetti P, et al. (2010). Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 10, 539.
64. Slamon DJ, and Press MF. (2009). Alterations in the TOP2A and HER2 genes: Association with adjuvant anthracycline sensitivity in human breast cancers. J Natl Cancer Inst 101, 615-618.
65. Smith MB, Reardon J, and Olson EM. (2012). Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer. Drugs Today (Barc) 48, 713-722.
66. Sørlie T, Perou CM, Tibshirani R, et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874.
67. Sotiriou C, and Piccart MJ. (2007). Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? Nat Rev Cancer 7, 545-553.
68. Staaf J, Jönsson G, Ringnér M, Baldetorp B, and Borg A. (2011). Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 13, R129.
69. Staaf J, Jönsson G, Ringnér M, et al. (2010). High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 12, R25.
70. St-Germain ME, Gagnon V, Parent S, and Asselin E. (2004). Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NFjB/IjB pathway. Mol Cancer 3, 7.
71. Streckfus CF, Arreola D, Edwards C, and Bigler L. (2012). Salivary protein profiles among HER2/neu-receptor-positive and-negative breast cancer patients: Support for using salivary protein profiles for modeling breast cancer progression. J Oncol 2012, 413256.
72. Surani MA, Hayashi K, and Hajkova P. (2007). Genetic and epigenetic regulators of pluripotency. Cell 128, 747-762.
73. Szklarczyk D, Franceschini A, Kuhn M, et al. (2011). The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39, D561-568.
74. Terada K, Okochi-Takada E, Akashi-Tanaka S, et al. (2009). Association between frequent CpG island methylation and HER2 amplification in human breast cancers. Carcinogenesis 30, 466-479.
75. Theillet C. (2010). What do we learn from HER2-positive breast cancer genomic profiles? Breast Cancer Res 12, 107.
76. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, and Grogan TM. (2001). Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19, 2714-2721.
77. Vazquez-Martin A, Colomer R, Menendez JA. (2008). Her-2/neu-induced "cytokine signature" in breast cancer. Adv Exp Med Biol 617, 311-319.
78. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, and Kennecke H. (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28, 1684-1691.
79. Wang S, Hossein Saboorian M, Frenkel EP, et al. (2002). Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 15, 137-145.
80. Wee EJH, Peters K, Nair SS, et al. (2012). Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast. Oncogene 20, 82-95.
81. Wirapati P, Sotiriou C, Kunkel S, et al. (2008). Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10, R65.
82. Wolff AC, Hammond ME, Schwartz JN, et al. (2007). American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131, 18-43.
83. Wu Y, Shang X, Sarkissyan M, Slamon D, and Vadgama JV. (2010). FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res 70, 5475-5485.
84. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, and Koay ES. (2005). Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4, 1686-1696.